Merck tumbles
En Bloomber.com podemos leer lo siguiente:
"The Dow average shed 55,97, or 0,6% to 10.080,27. Merck shares tumbled 27 percent and accounted for all of the average´s decline".
"Merck recorded its biggest tumble in at least 20 years, plunging $12,07 to $33. The second-largest U.S. drugmaker said the withdrawal of vioxx, wich generated $2,5 billion in sales last year. will reduce full-year profit by 50 cents to 60 cents a share. Merck is pulling the medication because of data showing an increased risk of heart attacks and strokes.
"Once you admit to that, the lawyers will come along and class-action suits will come along" , said Richard Sichel, chief investment officer at Philadelphia Trust Co., wich manages $1,2 billion and also owns Merck shares. "There are many negatives here; its not just lost revenues".
Merck´s drop wiped out $26,8 billion in market value, which is more than the value of General Motors Corp., the biggest automaker. The decline was the biggest percentage fall for a member of the Dow average in three years. About 145 million Merck shares traded, compared with a full-day average of 5,28 million shares the last three months".
Por si estáis interesados os adjunto el link a la nota de la FDA de la retirada del rofecoxib.
Tan sólo señalar, por lo que respecta al mercado español, que sólo en los últimos 12 meses se han vendido en España 900.000 unidades de "Vioxx", por un importe de 20 millones de euros (también se ha parado la comercialización de "Ceoxx", fármaco que no está financiado por el SNS). Este inhibidor de la COX-2, sirvió como tratamiento a 277.000 españoles durante el último año, según la compañía, aunque el Ministerio de Sanidad redujo la cifra a entre 70.000 y 100.000 los que pueden estar en tratamiento, principalmente mayores de 65 años.
"The Dow average shed 55,97, or 0,6% to 10.080,27. Merck shares tumbled 27 percent and accounted for all of the average´s decline".
"Merck recorded its biggest tumble in at least 20 years, plunging $12,07 to $33. The second-largest U.S. drugmaker said the withdrawal of vioxx, wich generated $2,5 billion in sales last year. will reduce full-year profit by 50 cents to 60 cents a share. Merck is pulling the medication because of data showing an increased risk of heart attacks and strokes.
"Once you admit to that, the lawyers will come along and class-action suits will come along" , said Richard Sichel, chief investment officer at Philadelphia Trust Co., wich manages $1,2 billion and also owns Merck shares. "There are many negatives here; its not just lost revenues".
Merck´s drop wiped out $26,8 billion in market value, which is more than the value of General Motors Corp., the biggest automaker. The decline was the biggest percentage fall for a member of the Dow average in three years. About 145 million Merck shares traded, compared with a full-day average of 5,28 million shares the last three months".
Por si estáis interesados os adjunto el link a la nota de la FDA de la retirada del rofecoxib.
Tan sólo señalar, por lo que respecta al mercado español, que sólo en los últimos 12 meses se han vendido en España 900.000 unidades de "Vioxx", por un importe de 20 millones de euros (también se ha parado la comercialización de "Ceoxx", fármaco que no está financiado por el SNS). Este inhibidor de la COX-2, sirvió como tratamiento a 277.000 españoles durante el último año, según la compañía, aunque el Ministerio de Sanidad redujo la cifra a entre 70.000 y 100.000 los que pueden estar en tratamiento, principalmente mayores de 65 años.
0 Comentarios:
Publicar un comentario
<< Home